| Serial Number | 99007677 |
| Word Mark | X |
| Filing Date | Friday, January 17, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Thursday, October 23, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 5 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, November 11, 2025 |
| Goods and Services | Providing venture capital, development capital, private equity and investment funding; Venture capital services, namely, providing financing to emerging and start-up companies; Providing venture capital, development capital, private equity and investment funding for the development of biologics, biosimilars, pharmaceuticals, and therapeutics; Venture capital services, namely, providing financing to emerging and start-up companies for the development of biologics, biosimilars, pharmaceuticals, and therapeutics |
| Indication of Colors claimed | The color(s) blue, purple, orange, and green is/are claimed as a feature of the mark. |
| Goods and Services | Research and development of biologics, biosimilars, pharmaceuticals, and therapeutics; Providing information in the field of scientific and medical research related to biologics, biosimilars, pharmaceuticals, and therapeutics |
| Description of Mark | The mark consists of the stylized letter "X", appearing in the colors blue, purple, orange, and green. The unenclosed white space appearing in the mark drawing, as well as the enclosed white space appearing in the center of the stylized letter "X", are background only. None of the white space appearing in the mark drawing is being claimed as a feature of the mark. |
| Goods and Services | Business consulting services; Business consulting services related to biologics, biosimilars, pharmaceuticals, and therapeutics; Market analysis and research services; Business advice and analysis of markets; Market analysis and research services related to biologics, biosimilars, pharmaceuticals, and therapeutics; Business advice and analysis of markets related to biologics, biosimilars, pharmaceuticals, and therapeutics |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 17, 2025 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 036 - Insurance; financial affairs; monetary affairs; real estate affairs. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 17, 2025 |
| Primary Code | 036 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, January 17, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Xentria, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Chicago, IL 60631 |
| Event Date | Event Description |
| Friday, January 17, 2025 | NEW APPLICATION ENTERED |
| Sunday, June 22, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, June 27, 2025 | ASSIGNED TO EXAMINER |
| Wednesday, July 16, 2025 | NON-FINAL ACTION WRITTEN |
| Wednesday, July 16, 2025 | NON-FINAL ACTION E-MAILED |
| Wednesday, July 16, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, October 8, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 8, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, October 14, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, October 15, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |